BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

China’s Akeso Completes Phase III Enrollment for Ivonescimab in Advanced Biliary Tract Cancer

Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study eva...

September 03, 2025 | News

South Korea’s SK bioscience Files IND for Global Phase 3 Trial of 2-Dose SKYVaricella Vaccine

Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 Rising demand for 2-dose regimen as internation...

September 03, 2025 | News

China’s Bon Natural Life Unveils Tea-Derived Compounds for Weight Management Through AI-Powered Drug Discovery

Bon Natural Life Limited , a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking identif...

September 03, 2025 | News

AstraZeneca Announces Positive Phase III Results for Baxdrostat, Demonstrating Significant Blood Pressure Reductions in Hard-to-Control Hypertension

AstraZeneca announced positive full results from the BaxHTN Phase III trial, showing that baxdrostat, a first-in-class aldosterone synthase inhibitor, achi...

September 02, 2025 | News

South Korea’s AMI Pharm Reports Phase 2 Success of ‘AYP-101,’ a Potential New Leader in Nonsurgical Fat Reduction

AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success 'AYP-101,' a Promising Nonsurgical Solution, H...

September 02, 2025 | News

Genentech and Alnylam Advance Zilebesiran into Phase III Outcomes Trial for Hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – ...

September 02, 2025 | News

Actinogen Confirms Commercial Tablet Formulation Of Xanamem Achieves Therapeutic Blood Levels

Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet form...

August 28, 2025 | News

Hope Biosciences Receives First RMAT Designation For Stem Cell Therapy In Multiple Sclerosis

Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has g...

August 28, 2025 | News

Akeso Reports Positive Phase 3 Results For Gumokimab In Ankylosing Spondylitis And Manfidokimab In Atopic Dermatitis

Akeso Inc. announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibod...

August 26, 2025 | News

Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager

Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...

August 26, 2025 | News

AbbVie To Acquire Gilgamesh’s Lead Psychedelic Compound Bretisilocin For Up To $1.2 Billion

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of m...

August 26, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

Lighthouse Pharma Secures $49.2M NIH Grant to Launch Phase 2 Alzheimer’s Trial in the United States

Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor Lighthouse Pharmaceuticals, a...

August 25, 2025 | News

SMSbiotech Launches First-in-Human Trial of Small Mobile Stem Cells for COPD in Australia

SMSbiotech, a San Diego–based leader in regenerative medicine, announced the initiation of its first-in-human Phase 1 clinical trial for C...

August 22, 2025 | News

Stay Connected